News

Supporting Indian Biotherapeutic Companies with Antibody Development

Fusion Antibodies Supply banner

Fusion Antibodies and BioTickle partnership delivers value with proprietary antibody discovery, engineering and cell line technologies

Fusion Antibodies, pre-clinical antibody discovery and development experts and BioTickle, their exclusive distributor in India, are providing local biopharmaceutical organisations with access to invaluable unique biopharmaceutical development capabilities.

As Dr Richard Jones, CEO of Fusion Antibodies explains, “We are proud of the support we can offer to the biotherapeutic developers in India who are working at the leading-edge of this global industry. Together with our clients, we are developing novel therapeutic candidates aimed at a range of diseases.” Richard continues, “We can also support organisations with the development of antibodies that are specifically engineered to neutralise the SARS-CoV-2 virus, which of course is one of the biggest challenges facing the world at the moment.”

Since the emergence of COVID-19, Fusion Antibodies has dedicated resources into developing a panel of unique protein antigens for use in discovery platforms. To date, the proteins have shown excellent profiles in terms of activity and scalability. Furthermore, the company has been awarded a grant from Invest Northern Ireland to expand their COVID-19 focused research to accelerate the discovery of novel therapeutic and diagnostic antibodies.

“Through BioTickle, Fusion Antibodies is well-placed to provide world-class support to Indian biopharmaceutical developers no matter their target therapeutic area, from infectious diseases to oncology,” states Richard. “Since 2001, we have been dedicated to the discovery and development of antibodies to help bring about a positive change in the healthcare industry. Our team of experts has guided hundreds of projects through critical preclinical stages, and many of our client’s projects have advanced to clinical stage trials. Preparing for the future is also at the forefront of Fusion Antibodies. To this, we continue to grow and invest in our technologies and team to ensure we can provide our customers with the support they will need as the industry evolves over the next 10 to 20 years.”

About Fusion Antibodies plc

Established in 2001 as a spin out from Queens University Belfast, Fusion Antibodies are a Collaborative Research Organisation (CRO) providing antibody discovery, engineering and supply, through to cell line development. The Company’s mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry.

Fusion Antibodies world-class humanization and antibody optimization platforms harnesses the power of the natural somatic hypermutation space. To address remaining market needs in antibody discovery, Fusion is creating a breakthrough fully human antibody library to capture the entire human antibody repertoire.

Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx™  platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.

About BioTickle

Established in 2012 with a vision to make biosimilars available and affordable to approximately 5 billion people living in the Asia Pacific region, BioTickle started by populating single use bioreactors and automating bioprocesses. Now the company offers end-to-end solutions for biotherapeutic development from discovery through to supply of material via relationships with companies such as Fusion Antibodies.

BioTickle’s expertise is in end-to-end processing with the company offering solutions to improve efficiencies at both the research & development and the industrial production levels. BioTickle incorporates new technologies and innovative process flows with laboratory simulations and stringent impact analysis on full operations to make recommendations to improve bioprocess efficiency.